EUVIMEDObjevte EUVIMED
Klinische Studie (Phase IV)VergleichsstudieRandomisierte kontrollierte Studie

Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome

Kee Huat Chuah iD, Qing Yuan Loo, Audrey Joe Chii Loh, Jing Yi Leong, Wah Loong Chan, Xin Hui Khoo, Kim Leng Wong, Sarala Panirsheeluam, Vicraman Natarajan, Ai Kah Ng, Hazreen Abdul Majid, Sanjiv Mahadeva iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70420 ↗

At a glance

Klinische Studie (Phase IV) in Alimentary Pharmacology & Therapeutics, 2026. Written by Kee Huat Chuah and 11 co-authors. Institution: Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Major MEDLINE topics: Diet, Carbohydrate-Restricted, Gastrointestinal Agents, Irritable Bowel Syndrome, Rifamycins. Cited 11 times so far (Crossref); 42 references. Funded by: UMSC C.A.R.E Research Grant.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Rifaximin and the low FODMAP diet (LFD) are suggested as second‐line therapies for irritable bowel syndrome (IBS). Direct comparative data are limited.

Aims

To compare the efficacy of rifaximin and LFD in IBS.

Methods

In this single‐blind, randomised controlled trial, we allocated adults with IBS to rifaximin or LFD. The primary outcome was composite symptom improvement (abdominal pain/discomfort and stool consistency/frequency) at Week 4. Secondary outcomes included individual symptom improvement, ≥ 50 point reduction in IBS Symptom Severity Scale (IBS‐SSS), health‐related quality of life (HRQOL), Hospital Anxiety and Depression Scale (HADS), small intestinal bacterial overgrowth (SIBO) eradication, adherence and adverse events.

Results

We randomised 100 patients equally (median age 50 years; 52% female; 68% IBS‐D; 17% SIBO). Based on the composite symptom assessment, response rates were similar between groups (rifaximin 56.0% vs. LFD 48.0%, p = 0.423) at Week 4. However, rifaximin led to significantly earlier individual symptom improvement at Week 2, including global symptoms (90.0% vs. 72.0%, p = 0.022), bloating (84.0% vs. 58.0%, p = 0.004) and abdominal pain (80.0% vs. 58.0%, p = 0.017). HRQOL and anxiety scores improved in both groups. SIBO eradication was observed in 63.6% (rifaximin) and 50.0% (LFD). Adherence was significantly better with rifaximin (95.9% vs. 77.8%, p = 0.008). No serious adverse events occurred.

Conclusion

Rifaximin is as effective as LFD in treating IBS over 4 weeks. However, it provides faster symptom relief and higher treatment adherence, making it a practical alternative for symptom management. Trial Registration ClinicalTrials.gov: NCT number: NCT04841980

Subjects

MeSH terms (MEDLINE)

Diet, Carbohydrate-RestrictedGastrointestinal AgentsIrritable Bowel SyndromeRifamycinsAdultFemaleHumansMaleMiddle AgedFODMAP DietQuality of LifeRifaximinSingle-Blind MethodTreatment Outcome

Author keywords

bacterial overgrowthdisorder of gut brain interactionirritable bowel syndromelow FODMAP dietrifaximin

Substances

Gastrointestinal AgentsRifamycinsRifaximin

Authors and institutions

  • Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Staff & Student Health Unit, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • School of Health Rehabilitation Sciences, Health Sciences University, Bournemouth, UK.

ORCID profiles: Kee Huat Chuah, Sanjiv Mahadeva

Funding

  • UMSC C.A.R.E Research Grant

Cite

APA

Chuah, K. H., Loo, Q. Y., Loh, A. J. C., Leong, J. Y., Chan, W. L., Khoo, X. H., Wong, K. L., Panirsheeluam, S., Natarajan, V., Ng, A. K., Abdul Majid, H., & Mahadeva, S. (2026). Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70420

Vancouver

Chuah KH, Loo QY, Loh AJC, Leong JY, Chan WL, Khoo XH, et al. Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70420

BibTeX
@article{Chuah2026,
  author = {Chuah, Kee Huat and Loo, Qing Yuan and Loh, Audrey Joe Chii and Leong, Jing Yi and Chan, Wah Loong and Khoo, Xin Hui and Wong, Kim Leng and Panirsheeluam, Sarala and Natarajan, Vicraman and Ng, Ai Kah and Abdul Majid, Hazreen and Mahadeva, Sanjiv},
  title = {Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70420}
}
Start for free →